ASCO Annual Meeting

ASCO 2026 data show ePRO remote symptom monitoring cuts ER visits and costs, enabling faster toxicity detection and safer community cancer care.

OncoPRO unites oncology practices to streamline ePRO remote symptom monitoring, improving enrollment, workflow integration, and change management through shared implementation strategies.

ASCO 2026 data show ePRO symptom tracking keeps cancer patients on therapy longer, cuts hospitalizations and costs, and may boost survival.

Real-world ASCO 2026 data show ePRO-based remote monitoring helps catch metastatic cancer treatment symptoms earlier, improving toxicity control and reducing hospitalizations.

ASCO 2026 real-world data tie GLP-1 drugs to longer cancer survival, but oncology EHRs miss timing and duration—heres why it matters.

Real-world community oncology data link GLP-1 drugs to 34% lower death risk across cancers, prompting calls for prospective trials.

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening.

Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

Puxitatug samrotecan is now being evaluated in the global phase 3 BLUESTAR-Endometrial-01 trial.

"These findings support carboplatin-based IC-CCRT as a promising alternative treatment option for LA-NPC," Jian Guan, MD.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.

Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast cancer from HER2CLIMB-05.

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with brain metastases at a single academic center.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Experts discuss their ASCO presentations on 3 rare disease states: uveal melanoma, mucosal melanoma, and Merkel cell carcinoma.

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

ASCO 2026 highlights: KRAS signals, ADC‑immunotherapy momentum, and new TNBC/HER2 breakthroughs shaping next breast cancer trials.

VIKTORIA-1 shows gedatolisib regimens double PFS and cut hyperglycemia vs alpelisib in PIK3CA-mutant HR+/HER2– breast cancer.

Living in food deserts links to aggressive ctDNA mutations and shorter metastatic breast cancer survival, with the starkest survival gaps seen in Black patients.

James W. Smithy, MD, MHS, discusses the key findings from a phase 2 trial of IO102-IO103 plus nivolumab/relatlimab in advanced melanoma.

Phase 2 study presented at ASCO 2026 shows fedratinib eases symptoms and shrinks spleens in rare MDS/MPN variants, offering a needed evidence-based option.

Allostatic load links chronic stress and social factors to early-onset cancer risk, offering a measurable path to improve risk models and prevention strategies.